Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Xiaoyin Tang

Rheumatology Neptune, NJ Medical Doctor

NPI 1437128568 CMS profile 109711

2240 Route 33, Suite B, Neptune, NJ 07753

Open in the dashboard

General payments

$4,974

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Xiaoyin Tang of Neptune, NJ is reported in the CMS Open Payments database as having received $4,974 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,682 60
2024 General $701 37
2023 General $626 40
2022 General $606 36
2021 General $279 20
2020 General $301 21
2019 General $779 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Xiaoyin Tang
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Xiaoyin Tang were reported at $1,682. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Xiaoyin Tang Rheumatology median Middle half National median
2019 $779 $744 $153–$2,687 $163
2020 $301 $462 $98–$2,027 $114
2021 $279 $531 $101–$2,153 $132
2022 $606 $627 $125–$2,303 $149
2023 $626 $741 $145–$2,524 $160
2024 $701 $830 $166–$2,660 $164
2025 $1,682 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,096 40 payments
  2. Amgen Inc. $469 30 payments
  3. GlaxoSmithKline, LLC. $437 23 payments
  4. Janssen Biotech, Inc. $423 18 payments
  5. Novartis Pharmaceuticals Corporation $252 14 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $226 9 payments
  7. Lilly USA, LLC $225 16 payments
  8. AstraZeneca Pharmaceuticals LP $190 12 payments
  9. E.R. Squibb & Sons, L.L.C. $174 12 payments
  10. Merck Sharp & Dohme Corporation $169 10 payments
  11. Other $1,313 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,830 265 payments
  2. Education $144 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $796 24 payments
  2. BENLYSTA $410 21 payments
  3. TREMFYA $396 16 payments
  4. Prolia $188 13 payments
  5. EVENITY $183 12 payments
  6. SAPHNELO $175 11 payments
  7. ORENCIA $174 12 payments
  8. XELJANZ $165 11 payments
  9. SKYRIZI $158 6 payments
  10. TALTZ $156 11 payments
  11. Other $2,876 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,135

Median for Rheumatology: 1,511

Drug cost

$1,520,114

Median for Rheumatology: $1,139,948

Branded share of claims

30%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 71 $573,312
Humira(Cf) Pen Adalimumab Brand 23 $209,718
Xeljanz Xr Tofacitinib Citrate Brand 34 $195,160
Taltz Autoinjector Ixekizumab Brand 22 $160,181
Enbrel Etanercept Brand 13 $93,238
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $92,695
Orencia Abatacept Brand 16 $81,465
Cimzia (2 Pack) Certolizumab Pegol Brand 11 $59,067
Hydroxychloroquine Sulfate Generic 228 $13,479
Methotrexate Methotrexate Sodium Brand 284 $11,388

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$344,601

Of which drugs: $264,982

Medicare patients

429

Average age 73

Services billed

50,990

340 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 37%
Osteoporosis 37%
Diabetes 31%
Depression 29%
Chronic kidney disease 25%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 19 40,800 $147,508
Injection, denosumab, 1 mg J0897 Office 30 2,400 $47,069
Injection, methylprednisolone acetate, 1 mg J1010 Office 46 3,181 $327
Injection, methylprednisolone acetate, 80 mg J1040 Office 11 11 $69

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $152
$152 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $54
$54 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $46
$46 — —
SKYRIZI
  • AbbVie, Inc. $45
$45 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record